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Regulatory T (Treg) cells maintain dominant control of immune responses to foreign materials and
microbes. Appropriate Treg cell suppression of immune responses is essential for the maintenance of
efficacious defensive responses and the limitation of collateral tissue damage due to excess
inflammation. Allergy and infection are well studied and frequent afflictions in which Treg cells play
an essential role. As such, they provide excellent models to communicate the significance and relevance
of Treg cells to complementary and alternative medicine (CAM).
Treg Ubiquity and Universality: Relations to
Foreign Bodies
The major principles underlying the dynamic immune system,
including constituents, interrelationships and feedback mecha-
nisms have been established, with emphasis on regulatory
T( T reg) cells (1). The goal of this article is (i) to detail
Treg cells, (ii) to delineate Treg cell function in allergy and
infection and (iii) to examine the pathological consequences
of aberrant Treg cell activity. Allergy and infection are well-
studied and frequent afflictions, and as such, they provide
excellent models to communicate the significance and rele-
vance of Treg cells to complementary and alternative medicine
(CAM).
Considerable inflammation, resulting from allergic hyper-
sensitivity or immune response to infection, has the potential
to induce deleterious effects on an individual’s tissues and
overall well-being. Recent evidence has served to elucidate
the mechanism of action and substantiate the usage of a
veritable array of traditional herbs, folk medicines and other
compounds found in nature, which have been employed to
attenuate inflammatory complications. Of interest to
practitioners, researchers and patients of CAM modalities are
those compounds that maintain powerful immunomodulatory
capacity via direct or indirect action on Treg cells (Table 1).
A cornucopia of herbal medicines has shown clinical effec-
tiveness in the attenuation of allergic and infection-induced
inflammatory pathology. Traditional therapeutics for allergic
complications includes immunotherapy, antihistamines and
glucocorticoids. A newly researched compound, termed anti-
asthma herbal medicine intervention (ASHMI), which is an
extract of three herbs, has shown effectiveness and benefit
over traditional treatment options for asthma. ASHMI mainly
downregulates TH2 cell responses, increases lung function
through direct modulation of smooth muscle contraction and
decreases peripheral blood eosinophils and serum IgE. ASHMI
does not induce a state of general immunosuppression like
steroids, such as prednisone, which suppress TH1 and TH2 cell
responses.
Treatment of infection with antimicrobial drugs poses
an array of complications, including resistance and physical
ailments, e.g. diarrhea. Allium sativum, extracted from garlic,
has the potential to bolster TH1 cell-mediated responses
to pathogens, such as Leishmania major. The proposed
mechanism includes enhancement of TH1 cytokine response,
T lymphocyte proliferation and NK cell activity. This method
of antimicrobial treatment offers benefits over pharmaceutical
drugs; however, its efficacy and mechanism of action needs
further research and elucidation.
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a scientific basis for confident treatment decisions, as it lends
credibility to CAM modalities and, most importantly, offers
efficacious treatment options to a large segment of the popula-
tion afflicted with allergic and infectious complications.
Knowledge of the dynamic relationship between Treg cells and
immune system responses to foreign antigens is essential in
order to approach Treg cells as a clinical target for the allevia-
tion of complications arising from allergy, asthma, dermatitis
and infection.
Treg Subsets: Three of a Kind
The family greatly responsible forimmunomodulation consists
of two key subsets: naturally arising and peripherally induced
Treg cells. Although the ontogenic relationship between the
two is not well understood, both subsets have been character-
ized by distinct differentiation patterns and functions (19).
Naturally Occurring Treg Cells
Naturally occurring Treg (nTreg) cells compose 5–10% of
peripheral T cells, maintain a distinct lineage and develop in
the thymus. nTreg cells are directed to largely aid in tolerance
to self-antigen in the periphery via suppressive actions on
both TH1 and TH2 cell-mediated immune responses, with
greater specificity for the former (20–24).
nTreg cells inhibitory action is contact dependent. Interaction
of CTLA-4 and TGF-b1, expressed on the cell surface, with
respective ligands and receptors on target cells, triggers the
downregulation of effector cell IL-2Ra receptors and a subse-
quent decrease in fitness (20,23,25). Alternate mechanisms
proposed include the perforin-dependent induction of T cell
apoptosis and the reduction of dendritic cell’s ability to prime
T cells, through direct suppression of cytokine secretion or
tryptophan metabolism (2,15,26–28).
Peripherally Induced Treg Cells
The adaptive Treg cell subset includes type 1 Treg (Tr1) cells
and T helper 3 (TH3) cells. Tr1 and TH3 cells are implicated
in immune responses to foreign antigens in the periphery,
alongside nTreg cells (22).
While extrathymic generation of Treg cells is not as well
understood as nTreg cell generation, Tr1 and TH3 cells are
derived from naı ¨ve T cells in an environment supporting suit-
able antigenic and cytokine stimulation (24,29). Located in
peripheral lymphoid tissue, these cells produce a distinct
cytokine profile upon TCR-mediated activation (22). Tr1 and
TH3 cells mediate immunosuppression through the secretion
of IL-10 and TGF-b1 (21,23,30,31). Tr1 and TH3 cells become
significant in peripheral self-tolerance when the pool of self-
antigen-specific nTreg cells is deficient (31).
Treg Cell Singularity
For the purposes of this review and owing to the fact that
definitive comparative research on the subsets is insufficient
for precise differentiation, nTreg,T r1 and TH3 cells will be
collectively referred to as Treg cells.
At One with Nature: Modulating Responses of
Allergenic Challenge
Aberrant immune responses to environmental allergens are
relatively common with wide variations in severity and mani-
festation. Depending on the allergen size and mode of expo-
sure, an atopic individual may experience afflictions ranging
from asthma to seasonal allergic rhinitis to atopic dermatitis.
Table 1. CAM compounds with regulatory capability and utility in
Allergy and Infection
Natural product Activity Reference
Brazilian green propolis Modulate initial
inflammation
(2,3)
Lower parasitemia
Ganoderma lucidum
(mycelia extract)
Activate kB DNA binding (4,5)
Increase TNF-a, IL-6, IFN-g
Inhibit histamine release
Phellinus linteus
(mycelia extract)
Lower TNF-a, IFN-g
production
(6)
Lower IgG levels
Piper methysticum (kava) Inhibit TNF-a release (7)
Induce NF-kB transcription
Allium sativum (garlic) Increase TH1 cytokine
response
(8)
Enhance macrophage and
NK cell activity
Increase T cell proliferation
( )-epigallocatechin
gallate (green tea)
Decrease IL-2, IFN-g,
TNF-a levels
(9)
Decrease T cell proliferation
Probiotics Induce Tr1 and TH3 induction (10–14)
Lactobacillus casei Propogates oral tolerance
BGN4 (Bifidobacterium
bifidum)
Decreases IgA and IgE
production
VSL #3 Dampens NF-kB
proinflammatory signals
Decreases levels of cell
degranulation
Staphyloccocal superantigen B Treg cell suppressor (2,15)
Ergosterol peroxide
(Tricholoma populinum)
Decreases allergic symptoms (5)
ASHMI Decreases TH2 response
and cytokines profile
(16,17)
Ganoderma lucidum Lowers IL-5, IL-13 and
IgE levels
Radix Sophora
flavescentis
Radix Glycyrrhiza
uralensis
KRN7000 Immunostimulantion (18)
Agelus mauritianus
derivative
Increases IFN-g, IL-4,
and IL-12
Enhances NK cell activity
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of IgE against environmental allergens, e.g. grass, house dust
mites, pollen and animal proteins (30,32). Allergen-specific
IgE, on the surface of mast cells and basophils, upon binding
to allergen, triggers the release of histamine and mediators
resulting in immediate symptomology (33). Often, patients
with allergic diseases have a deficient ability to suppress T
cell responses to allergen by Treg cells (32,34).
Treg cell’s role in the prevention of sensitization to allergens
has recently been explored (32). Evidence of significant Treg
cell suppressive action on TH2 cell-mediated immune
responses supports the notion that their depletion or functional
dysregulation may be responsible for atopic pathology (32).
Allergy
Seasonal allergic rhinitis, more commonly known as Hay
Fever, involves the deposition of allergens on the nasal mucosa
followed by an immediate hypersensitivity reaction. Allergens
involved, like grass pollen, are typically too large to enter
into the lower airways, rendering asthmatic complications
unusual. Treg cells have the capability to reduce or prevent
TH2 cell-mediated allergic rhinitis and atopic sensitization
disorders (32,34).
Allergen-specific Treg cells are also modulators of immune
response to dietary allergens and intimately involved in the
development of oral tolerance. Karlsson et al. illustrates Treg
cell functionality in an experiment utilizing children with
allergy to cow’s milk (35). A majority of the allergic children
developed oral tolerance to milk following a period of milk
restriction. Development of b-lactalbumin-specific Treg cells,
in those children who developed tolerance to cow’s milk,
was found to be responsible for the newfound tolerance.
Induction of tolerance to allergen, via antigen-specific Treg
cell generation, is noted in individuals encountering pollen,
dust mites and other environmental antigens (2,32). This signi-
fies the malleability of immune system response and balance
afforded by antigen-specific Treg cells (35,36).
Taken altogether, the response of an individual to allergen
encounter is dependent on many factors, including the
quantity and activity of antigen-specific Treg and the TH2
effector populations (36).
Asthma
Asthma is a chronic airway inflammatory disease triggered by
allergic exposure and hallmarked by airway inflammation,
bronchial hyperreactivity, lung eosinophilia and excessive
TH2 cytokine production (28,34).
Inappropriate TH2 cell response to inhaled allergens elicits
airway inflammation. The complex biosignaling cascade
resulting in asthma manifestation is mediated by the over pro-
duction of IL-4, IL-5, IL-9 and IL-13, which serves to regulate
IgE production and to sequester effector cells to the airway.
Effector cells that are directed towards airway tissues enhance
airway inflammation and hyperresponsiveness through the
generation of additional proinflammatory cytokines and
autocoids (32,37). In many cases, asthma pathology is due to
an excess of TH2 cell quantity or activity, leading to a skewing
towards a proinflammatory cytokine profile (28).
Mouse models of airway inflammation allow for the exam-
ination of allergen-specific Treg cells activity in vivo. The
transfer of ovalbumin (OVA) peptide-specific Treg cells to
OVA sensitized mice reduced TH2 type cytokine expression
in the lungs, airway hyperreactivity and effector cell recruit-
ment. The ameliorative effects were dependent upon IL-10;
however, TH2 cells were the source of IL-10 secretion, rather
than Treg cells (34). Treg cells may reduce inflammatory
response through a contact-dependent manner, e.g. enhancing
the secretion of IL-10 by TH2 cells.
Treg cells aid in the suppression of inflammatory responses
to inhaled antigen and are essential for the induction of aller-
genic tolerance. Administration of inhaled allergen, with prior
induction of allergen-specific Treg cells, prevents allergen
sensitization and airway inflammation upon later exposure.
Thus, immunotherapy offers a powerful function based on
the modulation of allergen-specific Treg cell suppression of
TH2 responses (32).
Dermatitis
Atopic dermatitis is a chronic inflammatory skin disorder in
which TH2 effector cells migrate to the dermis, and under
IL-12 conditions, become TH0o rT H1 cells. In atopic individu-
als, a dysregulation of effector T cells and an impairment of
Treg cell suppression are involved in the development of
inflammatory pathology (38). While various treatment options
exist, includingtheuseofsteroids,antihistamines andaggrega-
tive factor elimination, an increasing number of patients are
finding little relief and are requiring other therapeutic modali-
ties, some of which may be derived from CAM (39).
Throwing Water on the Inflammation:
Treg Cell’s Delicate Relations to
Infectious Pathology
To deal with microorganisms, the body has evolved intricate
defense mechanisms. The process of pathogen control involves
the recruitment of immune system cells to the site of infection.
Necessary components include inflammatory cells, cytotoxic
T cells and NK cells. The generation of antigen-specific
Treg cells is a crucial regulatory element in the immune
response to infection by bacteria, parasites, fungi and viruses,
as well as the fostering and maintenance of tolerance to
non-pathogenic microbes (21,40). Dysregulation of Treg cell-
mediated anti-inflammatory pathways poses potentially great
risks to health (41).
Effective immune response to pathogen is often accompa-
nied by a great deal of inflammation. In excess, this inflamma-
tion can cause collateral tissue damage and pathology that
necessitates the activation and proliferation of pathogen-
specific Treg cells (19,21,42–44; Fig. 1). Conversely, a
decrease in defense responsiveness owing to underlying
eCAM 2006;3(2) 211immunosuppression renders the host susceptible to pathogenic
infection and subsequent harm. Depending on a number of
variables, a reconstitution of immune system responses or
Treg cell populations may be necessary in lieu of appropriate
antimicrobial or inflammatory therapy.
Bacterial Infections
IL-10 secreting Treg cells attenuate bacterial-induced abnor-
malities caused by massive inflammation. This immunosup-
pressive cytokine is imperative for dampening excessive
inflammation, owing to TH1 responses and increase in TNF-
a production, while it is potentially detrimental to pathogen
attack, thus making the level of IL-10 in sites of inflammation
extremely delicate and specific (44).
A variety of bacterial-induced inflammatory diseases rang-
ing from peritonitis from Escherichia coli, to chronic gastritis
from Helicobacter pylori and to chronic hepatitis from
Helicobacter hepaticus, reinforce a correlation between
IL-10 deficiencies and disease severity. To illustrate this,
mice with a deficiency in IL-10, upon exposure to Listeria
monocytogenes, have a greater severity of brain lesions,
because of increased proinflammatory cytokine production in
the brain (44–46). In this instance, either specialized Treg cells
or their IL-10 secretions help to limit TH1 cell-mediated
inflammation and damage during infection.
Recognition of hazardous microbes, allergens and toxins
as pathogenic agents activates the gastrointestinal immune
system. Antigen-specific Treg cells, which mediate oral toler-
ance to commensal microbes, differentiate between harmless
inhabitants of the gut and pathogens. A break in the deve-
lopment or maintenance of oral tolerance may result in an
astounding array of detrimental inflammatory disorders,
including inflammatory bowl disease (IBD) and colitis.
IBD and colitis are conditions in which the immune
system of patients reacts excessively to indigenous intestinal
bacteria. Treg cell depletion in these disorders effectively
breaches tolerance and allows for massive inflammation
in the gut. In vivo transfer of Treg cells suppresses disease
development, through IL-10, TGF-b and CTLA-4-dependent
mechanisms (21).
Colonization of gastric and duodenal mucosa by H. pylori
induces strong immune responses involving innate immune
system cells as well as H. pylori-specific T and B cells (27).
Treg cells dampen the immune response to H. pylori,
effectively limiting acute infection-induced pathology, at the
cost of bacterial persistence and long-term pathology, i.e.
chronic infection (27). Prevention of inflammation via IL-10
and TGF-b may prove useful in the control of H. pylori
infection (21).
Interestingly, varieties of bacteria including Mycobacterium
tuberculosis, Yersinia entercolitica and Bordetella pertussis
induce production of IL-10 by macrophages. This cytokine
manipulation efficiently triggers immunosuppression and
attenuates bacterial attack, by means of inducing development
of IL-10 secreting Treg cells (46,47).
The appropriate balance between inflammation and bacterial
destruction so that the body accrues minimal tissue damage
while putting up adequate host defense as well as development
of tolerance to commensals are essential roles of IL-10
secreting Treg cells. Thus, they pose a promising target for
the suppression of extreme inflammation and tissue damage
during bacterial exposure or infection. It is important to note
that different clinical outcomes may result from Treg cell
activation status.
Fungal Infections
Treg cell activation limits inflammatory pathology induced
by fungal infection but compromises fungal clearance.
Pneumocystis carinii and Candida albicans are used in models
to ascertain Treg cell function. Infection of Treg cell deficient
mice with P. carinii yields fatal pulmonary inflammation,
with damage owing to CD4
þ effector T cells. Treg cell infusion
prevents inflammation and disease development at the cost of
increased pathogen load (19,21,48–50). Similarly, Treg cell
depletion renders adequate control of C. albicans infection
Figure 1. Modulation of TH1 cell immune response by Treg cells and CAM.
Sites of action throughout the TH1 cell-mediated inflammatory pathway.
A, Brazilian green propolis; B, Ganoderma lucidum;C ,P. linteus;D ,Piper
methysticum;E ,Allium sativum;F ,(  )-epigallocatechin gallate; G,
KRN7000; H, probiotics; I, Staphylococcal superantigen B; J, Ergosterol
peroxide.
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ensue (21).
Parasitic Infections
IL-10 or TGF-b secreting Treg cells have great utility in the
balance between parasite clearance and induced immuno-
pathology, as seen in malarial, Plasmodium chabaudi and
L. major infections.
The severity of malarial infection directly correlates to the
ratio of TGF-b and IL-10 levels to TNF-a levels, i.e. a greater
proportion of suppressive cytokines attenuates severity of
infection-inducedinflammation.IL-10-deficientmice,infected
with P. chabaudi, maintain severe infection and massive
inflammatory responses resulting in significant host damage
(44,51–53). In the case of L. major infection, removal of Treg
cells results in the effective parasite clearance, however bad
lesions and a robust TH2 response ensue (19,21,27,54). This
substantiates the importance of TGF-b and IL-10 secreting
Treg cells in controlling parasitic infection and pathology.
Various parasites that have adapted to Treg cell host-defense
mechanisms have the ability to modulate Treg cell cytokine
production and activation (55–57). Therefore, the role of Treg
cells in inflammatory pathology and pathogen clearance may
vary significantly between individual parasitic infectious
agents.
Viral Infections
Treg cells reduce the severity of immune-mediated inflamma-
tory lesions in viral-induced diseases through the suppression
of pathogenic CD4
þ T cell activity and the limitation of
inflammatory cell sequestration.
Chronic hepatitis C virus infection results in massive
hepatic inflammation and damage. In liver biopsies, there is
an inverse correlation between peripheral Treg cells and histo-
logical inflammatory score (21). Treg cells, specifically those
secreting IL-10, are essential for the attenuation of such organ
detriment.
Theiler’s virus induces murine encephalomyelitis, a TH1
cell-mediated inflammatory disease of the central nervous sys-
tem, and provides a model of human multiple sclerosis from
which exploration of Treg cell functionality in autoimmune
detriment is possible. B cell proliferation and autoantibody
production, in some viral infections, plays a major role in
the development of viral-induced autoimmunity (51,58).
Infected mice may experience acute encephalomyelitis or
chronic demyelinating disease depending on the strain. Virus-
specific Treg cells sufficiently suppress this aberrant CD4
þ
TH1 cell-mediated response (59). Treg cell modulation of
reactions to self, regardless of causation, holds promising
implications for a broad spectrum of deleterious autoimmune
diseases.
During chronic viral infections, Treg cells are beneficial to
the host by maintaining a balance between efficient viral
defense and inflammation, while preventing the induction of
autoimmune disorders (56–63). Similar to other pathogens,
certain viruses, like HIV, have developed mechanisms that
directly affect Treg cell function, resulting in reduced antiviral
response and increased viral persistence (62–65).
The Maginot Line: Treg Cell’s Blockade of
Allergic and Infectious Immune Responses
Innovative research and subsequent elucidation of Treg cell
involvement in various atopic and infectious pathologies opens
up numerous avenues for ameliorative therapies while describ-
ing mechanisms of disease pathogenesis. It is apparent that the
Treg cell quantity and activation state are integral and equally
important factors in the development and maintenance of
inflammatory immunopathology (36).
Treg cell involvement in immune response to pathogens is
delicate since Treg cells actively suppress immunopathology
during infection, while concomitantly supporting persistence
of infection during chronic disease. Aberrant modulation of
immune responses by Treg cells may be owing to inappropriate
quantity or functionality of Treg cells. Excessive immune sup-
pression results in enhanced pathogen survival, through clear-
ance inhibition, which may lead to long-term persistence,
pathogen damage and increased potential for transmission
(21). On the other hand, depressed Treg cell activity allows
little control of inflammatory responses resulting in collateral
tissue damage (21,41). A balance between effector T and Treg
cell responses in sites of chronic infection may allow parasite
survival in host while maintaining host immune memory and
control of the pathogen (44).
Pathogens are evolving self-serving strategies to increase
survival potential, through the establishment of favorable con-
ditions for Treg cell priming, recruitment and survival (21).
Certain pathogens and their products, e.g. Staphylococcal
superantigen B, HTLV-1 and HIV, directly target and modu-
late Treg cell function (2). Evolved pathogen mechanisms for
Treg cells manipulation underscores the power and utility that
Treg cells hold and presents another means for medical treat-
ment of related diseases, e.g. implementation of means to
effectively antagonize pathways in which pathogens directly
modulate Treg cell functioning.
Increased research is necessary in order to determine Treg
cell functioning in relation to individual allergic and pathogen
induced disease states. This will afford CAM researchers
insight into the appropriate means of approaching a variety
of human disorders with respect to Treg cells.
Treg cell’s essential role in the management of allergy and
infection has been detailed using specific allergens or patho-
gens as examples. Harmony between regulatory and effector
arms of the immune system is a necessity for good health.
Treg cell intricacy and specificity to individual allergens or
pathogens impels further research and highlights Treg cells
overall importance to human health and CAM. The conceptual
framework laid down is consistent with various disease states,
including autoimmunity and tumor pathogenesis, which will
be a futile subject.
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